AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Vernalis drug shown to be effective in preventing menstrual migraine.(Vernalis Group PLC)(Brief Article)
M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD
British biopharmaceutical company Vernalis Group Plc has revealed positive results from a study of its frovatriptan migraine treatment in menstrual migraine sufferers.
The Phase IV clinical trial showed that the recently-launched anti-migraine treatment was highly effective in preventing menstrually-associated migraine headaches. A total of 52% of patients involved in the placebo-controlled trial were completely headache-free during the six-day period when they took 5mg of frovatriptan daily, and 41% were headache-free at a daily dose of 2.5mg, compared to only 26% who took the placebo.
Vernalis will …
-
- Vernalis Group plc Announces Sale of ApokynA[R] and US Commercial Operations...
-
News wire article from: Fair Disclosure Wire
June 5, 2008
700+ words
-
- Interim 2007 Vernalis Group plc Earnings Conference Call - Final.
-
News wire article from: Fair Disclosure Wire
September 13, 2007
700+ words
-
- Preliminary 2007 Vernalis Group plc Earnings Presentation - Final.
-
News wire article from: Fair Disclosure Wire
April 25, 2008
700+ words
-
- Migraine treatment from Vernalis introduced in US. (Vernalis Group PLC's...
-
Newspaper article from: M2 Europharma
June 28, 2002
700+ words
-
- Preliminary 2006 Vernalis Group plc Earnings Conference Call - Final.
-
News wire article from: Fair Disclosure Wire
March 12, 2007
700+ words
